Asuragen to Present at 2019 ACMG Annual Clinical Genetics Meeting

Asuragen, Inc., a molecular diagnostics company delivering high-quality, easy-to-use products for complex testing in genetics and oncology, will showcase its new genetics products at the upcoming ACMG Annual Clinical Genetics Meeting on April 2-6 in Seattle, Washington.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Tuesday, March 26, 2019
Information
Tags: 
Technology, Software, Health, Biotechnology, Genetics, Medical devices, Pharmaceutical, Research, Science, Medical genetics, Life sciences, Biotechnology, Molecular diagnostics, Biology, Health
Geotags: 
United States, Texas
⚠generated by AI ↴
Summary
Key Points: 
  • Asuragen, Inc., a molecular diagnostics company delivering high-quality, easy-to-use products for complex testing in genetics and oncology, will showcase its new genetics products at the upcoming ACMG Annual Clinical Genetics Meeting on April 2-6 in Seattle, Washington.
  • Our proprietary AmplideX chemistries allow analysis of these genes by laboratories everywhere and can help accelerate clinical research to advance our understanding of these debilitating conditions.
  • Asuragen is a molecular diagnostic company changing the way patients are treated in genetics and oncology.
  • Asuragens diagnostic systems, composed of proprietary chemistry and software, deliver powerful answers using broadly installed instrument platforms.


Asuragen, Inc., a molecular diagnostics company delivering high-quality,
easy-to-use products for complex testing in genetics and oncology, will
showcase its new genetics products at the upcoming ACMG Annual Clinical
Genetics Meeting on April 2-6 in Seattle, Washington. The company’s most
recent portfolio additions, the AmplideX® PCR/CE HTT*
and PCR/CE SMN1/2* Kits, will be featured in a pair of
poster presentations highlighting their rapid turnaround compared to
standard methodologies, reliable performance, and harmonized testing
workflows.

Asuragen’s posters will be presented during the poster session on
Thursday, April 4 from 10:00 – 11:30 a.m.

Poster 409:
Two-site Evaluation of a Rapid, Multiplexed
PCR/CE Assay for Assessment of Spinal Muscular Atrophy SMN1 and SMN2
Copy Number Status (Stela Filipovic-Sadic)

Poster 767:
Evaluation of the AmplideX® PCR/CE HTT
Kit for the Rapid and Accurate Genotyping of CAG Repeat Expansions (Darshana
Patel)

“With our rapidly growing product portfolio, we continue to provide
simple, scalable, and easy-to-implement testing solutions for
challenging genomic targets, many of which are implicated in
neurodegenerative and neurodevelopmental diseases,” said Matthew
McManus, MD, PhD, president and CEO of Asuragen. “Our proprietary
AmplideX chemistries allow analysis of these genes by laboratories
everywhere and can help accelerate clinical research to advance our
understanding of these debilitating conditions.”

The company will also have a presence at booth #828 during the
conference.

* For research use only. Not for use in diagnostic procedures.

About Asuragen

Asuragen is a molecular diagnostic company changing the way patients are
treated in genetics and oncology. The quality, simplicity and
sensitivity of its products brings precision medicine within reach.
Asuragen’s diagnostic systems, composed of proprietary chemistry and
software, deliver powerful answers using broadly installed instrument
platforms. They are simple to adopt and expand the ability to serve
patients. Asuragen is a product foundry rapidly and efficiently
addressing current and emerging clinical needs, including cancer
diagnosis and monitoring, reproductive health and aging, serving
laboratories across a patient’s lifespan with its best in class
diagnostic tests. For more information, visit www.asuragen.com.

Copyright: 
Copyright Business Wire 2019